We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+13.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$25B
AUM Growth
+$2.35B
Cap. Flow
+$638M
Cap. Flow %
2.55%
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$358M
2
PRLD icon
Prelude Therapeutics
PRLD
+$286M
3
KYMR icon
Kymera Therapeutics
KYMR
+$59.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$55.5M
5
NRIX icon
Nurix Therapeutics
NRIX
+$45.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$94.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.6M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$21.6M
4
INSM icon
Insmed
INSM
+$21.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
101
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$1.76M 0.01%
12,412
-660
-5% -$110K
BLCM
102
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.64M 0.01%
249,123
– –
MTEM
103
DELISTED
Molecular Templates, Inc.
MTEM
$1.63M 0.01%
9,921
-627
-6% -$111K
OYST
104
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.44M 0.01%
68,228
-3,200
-4% -$74.8K
ORTX
105
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.41M 0.01%
34,320
-6,250
-15% -$323K
CPRX
106
DELISTED
Catalyst Pharmaceutical
CPRX
$1.41M 0.01%
474,400
-25,600
-5% -$100K
GTH
107
DELISTED
Genetron Holdings Limited ADS
GTH
$1.19M ﹤0.01%
+33,333
New +$1.28M
CYPH
108
Cypherpunk Technologies Inc
CYPH
$153M
$1.11M ﹤0.01%
55,971
-41,874
-43% -$808K
EVFM
109
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$1.02M ﹤0.01%
28,870
-66,130
-70% -$2.87M
APLT
110
DELISTED
Applied Therapeutics
APLT
$790K ﹤0.01%
38,034
-27,900
-42% -$725K
GLMD icon
111
Galmed Pharmaceuticals
GLMD
$4.48M
$725K ﹤0.01%
143
-7
-5% -$45.7K
INFI
112
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$679K ﹤0.01%
580,400
– –
ADMS
113
DELISTED
Adamas Pharmaceuticals
ADMS
$675K ﹤0.01%
163,830
-8,800
-5% -$34K
AFMD
114
DELISTED
Affimed
AFMD
$643K ﹤0.01%
18,980
-1,020
-5% -$38.6K
ARAV
115
DELISTED
Aravive, Inc. Common Stock
ARAV
$357K ﹤0.01%
75,854
-168,201
-69% -$1.19M
GNFT
116
DELISTED
Genfit
GNFT
$150K ﹤0.01%
28,396
– –
VIRX
117
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$66K ﹤0.01%
15,162
-743
-5% -$6.49K
ABEO icon
118
Abeona Therapeutics
ABEO
$348M
– –
-63,627
Closed -$4.64M
MRKR icon
119
Marker Therapeutics
MRKR
$23.2M
– –
-24,051
Closed -$498K
MTNB icon
120
Matinas BioPharma
MTNB
$2.92M
– –
-41,928
Closed -$1.62M
TCDA
121
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-787,582
Closed -$21.6M
AIMT
122
DELISTED
Aimmune Therapeutics
AIMT
– –
-673,908
Closed -$11.3M
PRNB
123
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-1,580,873
Closed -$94.5M
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2020 Portfolio in Review

As of Q3 2020, Julian Baker held 126 positions worth $25B, up 10% from $22.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2020 filing shows 11 new, 17 increased, 63 reduced and 6 closed positions. Its largest new stake was Prelude Therapeutics: 10,118,636 shares worth $305M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2020 buy was Prelude Therapeutics: 10,118,636 shares worth $305M.
  • Julian Baker added most to BeOne Medicines Ltd in Q3 2020, an estimated $358M increase.
  • Julian Baker's biggest Q3 2020 reduction was Neurocrine Biosciences, cutting an estimated $26.6M.
  • Julian Baker fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $94.5M.
  • Julian Baker's ten largest holdings make up 86% of its $25B portfolio in Q3 2020.
  • Julian Baker opened 11 new positions and closed 6 in Q3 2020.
  • Julian Baker's portfolio value rose 10% quarter-over-quarter to $25B.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.